Who we are
Our sole focus is to develop technologies to maximise the destructive effect of radiation on tumours whilst minimising damage to healthy tissues. Our goal is to help healthcare providers and hospitals expand their repertoire of treatments to ensure clinicians and patients have choices. Advanced Oncotherapy's aim is to cost-effectively deliver the next generation of proton therapy which is clinically superior to the currently available alternative radiation therapies.
Advanced Oncotherapy plc has its head office in London, UK, its R&D facility, ADAM S.A. (Applications of Detectors and Accelerators to Medicine), at CERN, the European Organisation for Nuclear Research, in Geneva, Switzerland and has operations in Syracuse, USA.
Advanced Oncotherapy plc is a public limited company in England and Wales; company number 05564418 with registered offices on Level 17, Dashwood House, 69 Old Broad Street, London, EC2M 1QS. The Company’s shares are listed on the AIM market of the London Stock Exchange under the symbol AVO.L